Anne-Sophie Hamy1,2, Lauren Darrigues3, Enora Laas3, Diane De Croze4, Lucian Topciu5, Giang-Thanh Lam3,6, Clemence Evrevin2, Sonia Rozette2, Lucie Laot3, Florence Lerebours2, Jean-Yves Pierga2,3, Marie Osdoit3, Matthieu Faron7, Jean-Guillaume Feron3, Marick Laé5, Fabien Reyal2,3. 1. Residual Tumor & Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer, Institut Curie, Paris, France. 2. Department of Medical Oncology, Institut Curie, Saint-Cloud, France. 3. Department of Surgery, Faculté de Médecine Descartes, Université Paris, Institut Curie, Paris, France. 4. Department of Tumor Biology, Institut Curie, Saint-Cloud, France. 5. Department of Tumor Biology, Institut Curie, Paris, France. 6. Department of Gynecology and Obstetrics, Geneva University Hospitals, Geneva, Switzerland. 7. Department of biostatistics and epidemiology, INSERM 1018 CESP Oncostat team, Gustave Roussy Cancer Campus, Villejuif, France.
Abstract
INTRODUCTION: The Residual Cancer Burden (RCB) quantifies residual disease after neoadjuvant chemotherapy (NAC). Its predictive value has not been validated on large cohorts with long-term follow up. The objective of this work is to independently evaluate the prognostic value of the RCB index depending on BC subtypes (Luminal, HER2-positive and triple negative (TNBCs)). METHODS: We retrospectively evaluated the RCB index on surgical specimens from a cohort of T1-T3NxM0 BC patients treated with NAC between 2002 and 2012. We analyzed the association between RCB index and relapse-free survival (RFS), overall survival (OS) among the global population, after stratification by BC subtypes. RESULTS: 717 patients were included (luminal BC (n = 222, 31%), TNBC (n = 319, 44.5%), HER2-positive (n = 176, 24.5%)). After a median follow-up of 99.9 months, RCB index was significantly associated with RFS. The RCB-0 patients displayed similar prognosis when compared to the RCB-I group, while patients from the RCB-II and RCB-III classes were at increased risk of relapse (RCB-II versus RCB-0: HR = 3.25 CI [2.1-5.1] p<0.001; RCB-III versus RCB-0: HR = 5.6 CI [3.5-8.9] p<0.001). The prognostic impact of RCB index was significant for TNBC and HER2-positive cancers; but not for luminal cancers (Pinteraction = 0.07). The prognosis of RCB-III patients was poor (8-years RFS: 52.7%, 95% CI [44.8-62.0]) particularly in the TNBC subgroup, where the median RFS was 12.7 months. CONCLUSION: RCB index is a reliable prognostic score. RCB accurately identifies patients at a high risk of recurrence (RCB-III) with TNBC or HER2-positive BC who must be offered second-line adjuvant therapies.
INTRODUCTION: The Residual Cancer Burden (RCB) quantifies residual disease after neoadjuvant chemotherapy (NAC). Its predictive value has not been validated on large cohorts with long-term follow up. The objective of this work is to independently evaluate the prognostic value of the RCB index depending on BC subtypes (Luminal, HER2-positive and triple negative (TNBCs)). METHODS: We retrospectively evaluated the RCB index on surgical specimens from a cohort of T1-T3NxM0 BC patients treated with NAC between 2002 and 2012. We analyzed the association between RCB index and relapse-free survival (RFS), overall survival (OS) among the global population, after stratification by BC subtypes. RESULTS: 717 patients were included (luminal BC (n = 222, 31%), TNBC (n = 319, 44.5%), HER2-positive (n = 176, 24.5%)). After a median follow-up of 99.9 months, RCB index was significantly associated with RFS. The RCB-0 patients displayed similar prognosis when compared to the RCB-I group, while patients from the RCB-II and RCB-III classes were at increased risk of relapse (RCB-II versus RCB-0: HR = 3.25 CI [2.1-5.1] p<0.001; RCB-III versus RCB-0: HR = 5.6 CI [3.5-8.9] p<0.001). The prognostic impact of RCB index was significant for TNBC and HER2-positive cancers; but not for luminal cancers (Pinteraction = 0.07). The prognosis of RCB-III patients was poor (8-years RFS: 52.7%, 95% CI [44.8-62.0]) particularly in the TNBC subgroup, where the median RFS was 12.7 months. CONCLUSION:RCB index is a reliable prognostic score. RCB accurately identifies patients at a high risk of recurrence (RCB-III) with TNBC or HER2-positive BC who must be offered second-line adjuvant therapies.
Authors: Christine V Pestana; Chad A Livasy; Erin E Donahue; Brittany Neelands; Antoinette R Tan; Terry Sarantou; Lejla Hadzikadic-Gusic; Richard L White Journal: Ann Surg Oncol Date: 2022-07-09 Impact factor: 4.339
Authors: Adam L Maddox; Matthew S Brehove; Kiarash R Eliato; Andras Saftics; Eugenia Romano; Michael F Press; Joanne Mortimer; Veronica Jones; Daniel Schmolze; Victoria L Seewaldt; Tijana Jovanovic-Talisman Journal: Cancers (Basel) Date: 2022-06-04 Impact factor: 6.575
Authors: Milos Holanek; Iveta Selingerova; Pavel Fabian; Oldrich Coufal; Ondrej Zapletal; Katarina Petrakova; Tomas Kazda; Roman Hrstka; Alexandr Poprach; Maria Zvarikova; Ondrej Bilek; Marek Svoboda Journal: Diagnostics (Basel) Date: 2022-07-18